Clinical Trial Update: An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating OV101 for Angelman syndrome was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• OV101 (gaboxadol) (gaboxadol)

Snippet

Sponsor: Healx AI | Conditions: Angelman Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2025-07-18